A federal district court in Miami has issued a preliminary injunction in favor of an American biotechnology company that filed a lawsuit against two health care networks for an alleged fraudulent scheme valued in the millions of dollars.

And for lawyers litigating these types of cases, the outcome shows the measures biotechnology companies, such as Gilead Sciences, might have to take to safeguard their drugs and medical products to prevent fraud, and the numerous steps it can take to put a stop to these networks allegedly perpetrating these actions, said Maria D. Garcia, a partner and co-chairwoman of the health care practice at Kozyak Tropin & Throckmorton in Miami who is not involved in this case.